ISPOR 2022

Share on:

Saturday, May 14 - Thursday, May 19, 2022

Conference Website

The Future of HEOR in Patient-Driven Digital Healthcare Systems

We are looking forward to seeing you face-to-face at the conference! Take a look at our contributions and who will be attending below. Reach out to meet up with one of our researchers or find us at booth #322.

See who's attending

Schedule

Both in-person and virtual conference registration includes extended access to all session playback recordings as well as virtual posters and networking through June 17, 2022. All times are shown in ET.

Pre-Conference Presentations

May 10, 2:00 pm then on demand

Podium Presentation P65

Cost-effectiveness of every two month Cabotegravir long-acting (CAB-LA) compared with daily oral Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) for pre-exposure Prophylaxis (PrEP) to prevent HIV-1 infection in the United States. Davis A, Brogan A, Mellott CE, Fraysse J, Oglesby A.

Presentations

May 15, 1:00 - 5:00 pm

Short Course

Budget impact analysis 1: a 6-step approach. Davis AE, Earnshaw SR, Mullins CD.

May 16, 9:00 - 10:00 am

Poster Tour

The public health impact of routine vaccination in 16-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Yi Z, Graham J, Diaz-Decaro J, Myers E, Buck P.

May 16, 11:45 am - 12:45 pm

Forum

Measuring health preferences of multiple stakeholders: issues and challenges. Bridges JFP, Poulos C, Andrew Finkelstein E.

Speaker: Christine Poulos, PhD

May 16, 3:00 - 5:00 pm

Poster Session 2, MSR 17

Logical soundness in a discrete choice experiment study of benefit risk preferences. Poulos C, Ng X, Mansfield C, Rosenberg S, Peay H, Lee J, Irony T, Ho M.

Presenters will be with their posters from 5:30 - 6:30 pm.

May 17, 10:15 - 11:15 am

Workshop W16

Are we patient and care-partner centric enough in early Alzheimer's disease clinical trials? The potential limitations of using legacy clinical outcome assessments (COA) in the new era of Alzheimer's disease drug development. Harrison JE, Paulsen R, Acaster S, Herring W.

May 17, 1:30 - 2:30 pm

Workshop W17

Posters

Driving outcomes in mild cognitive impairment/Alzheimer's disease - a review of association between driving simulator measures and clinical outcomes assessments. Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Petrillo Billet J.

Estimating the number of individuals needed to treat with different pre-exposure Prophylaxis options to avoid 1 new HIV-1 infection in the United States. Oglesby A, Davis AE, Mellott CE, Fraysse J, Swygard H, Brogan A.

Impact of Huntington's disease on driving: a review of driving simulator measures and association with clinical outcomes assessments. Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Billet JP.

Cost-effectiveness of 3-antigen vs. single-antigen vaccine for prevention of hepatitis B in adults in the United States. Anderson S, Talbird SE, Nossov M, Beattie N, Diaz-Mitoma F.

AD valorem: Alzheimer's disease, atopic dermatitis, and challenges for value assessment in chronic conditions. Herring W, Mladsi DM, Ronquest NA.

A systematic review of the efficacy, safety and immunogenicity of plague vaccines. Hartley L, Harold S, Hawe E.

Real-world treatment patterns and healthcare resource utilization among patients diagnosed with erythropoietic protoporphyria and x-linked protoporphyria: results from a US electronic medical records study. Ciepielewska M, Hagan M, Houghton K, Hitchens A, Ansquer V, Silver SM.

Comparison of healthcare resource utilization and costs in patients with and without Bullous Pemphigoid: a retrospective analysis of US health insurance claims data. Xu X, Datto C, Kwiatek J, Meyers J, Candrilli S, Mines D, Stirnadel-Farrant H.

Understanding the patient experience of erythropoietic protoporphyria and x-linked protoporphyria: a qualitative study. Whalley D, Belongie K, Frangiosa T, Krasa H, Mladsi DM, Twiss J, Wolowacz S.